key: cord-0291978-ud8fxc99
authors: Nelson, Christine E.; Namasivayam, Sivaranjani; Foreman, Taylor W.; Kauffman, Keith D.; Sakai, Shunsuke; Dorosky, Danielle E.; Lora, Nickiana E.; Brooks, Kelsie; Potter, E. Lake; Roederer, Mario; Sher, Alan; Weiskopf, Daniela; Sette, Alessandro; de Wit, Emmie; Hickman, Heather D.; Brenchley, Jason M.; Via, Laura E.; Barber, Daniel L.
title: Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues
date: 2022-01-07
journal: bioRxiv
DOI: 10.1101/2022.01.06.475282
sha: c2aaa351a39c356aaa66ade04a689d38de795fda
doc_id: 291978
cord_uid: ud8fxc99

SARS-CoV-2 primarily replicates in mucosal sites, and more information is needed about immune responses in infected tissues. We used rhesus macaques to model protective primary immune responses in tissues during mild COVID-19. Viral RNA levels were highest on days 1-2 post-infection and fell precipitously thereafter. 18F-fluorodeoxyglucose (FDG)-avid lung abnormalities and interferon (IFN)-activated myeloid cells in the bronchoalveolar lavage (BAL) were found on days ∼3-4. Virus-specific effector CD8 and CD4 T cells were detectable in the BAL and lung tissue on days ∼7-10, after viral RNA, lung inflammation, and IFN-activated myeloid cells had declined. Notably, SARS-CoV-2-specific T cells were not detectable in the nasal turbinates, salivary glands, and tonsils on day 10 post-infection. Thus, SARS-CoV-2 replication wanes in the lungs prior to T cell responses, and in the nasal and oral mucosa despite the apparent lack of Ag-specific T cells, suggesting that innate immunity efficiently restricts viral replication during mild COVID-19. ONE SENTENCE SUMMARY SARS-CoV-2 infection leads to mild, focal lung inflammation, and type I IFN activated myeloid cells that mostly resolve prior to the influx of virus-specific effector T cells or antibody responses in rhesus macaques.

Six, male rhesus macaques were infected with SARS-CoV-2/USA-WA-1 at 1x10 6 105 tissue culture infectious dose (TCID)50 intranasally (i.n.) and 1x10 6 TCID50 intratracheally 106 (i.t.), for a total dose of 2x10 6 TCID50 (Table 1) . 18 FDG PET/CT imaging showed evidence 107 of heterogeneous inflammatory foci with increased 18 FDG uptake (Fig 1A, B) and lesion 108 density (Fig 1A, C) in the lungs of 5 of 6 animals at day 3 post-infection, which resolved 109 by day 9. Total genomic Nucleocapsid (gN) and subgenomic Nucleocapsid (sgN) RNA 110 levels from nasal and throat swabs peaked 1 to 2 days post-infection and decreased to 111 undetectable levels by day 7 to 10 ( Fig 1D) . Viral RNA was also found in the BAL of all 112 animals at day 4 post-infection and was mostly cleared by day 7-10. It should be noted 113 that day 4 post-infection likely does not represent the peak of viremia in the BAL, and 114

previous studies indicate peak viral loads are reached at day 1 post infection in the BAL 44 . 115 Viral RNA was essentially absent from plasma at all timepoints, consistent with previous 116

The animals were necropsied at day 10 post-infection for tissue analysis. A 3D 118 reconstruction of the day 3 PET/CT images with conducting airways was used to locate 119 and individually collect the previously PET hot lung regions and normal lung tissue 120 separately. SARS-CoV-2 gN RNA was found on day 10 in all secondary lymphoid organs 121 (SLO) and non-lymphoid tissues (NLT) tested, including the previously PET hot and 122 normal lung tissue, nasal turbinates, salivary gland, and tonsils ( Fig 1E) . sgN RNA was 123 present at lower levels compared to gN RNA, and was highest in lung tissue (Fig 1F) . The 124 persistence of viral RNA at day 10, was confirmed with RNA scope immunohistochemical 125 analysis ( Fig 1G) . There was a correlation between genomic and subgenomic RNA levels 126 in the mucosal swabs, BAL, and tissues with detectable RNA (Fig S1A-C) . We did not 127 observe a correlation between lung lesion severity at day 3 and viral RNA levels from 128 nasal swabs and BAL at day 1 and 4, respectively (Fig S1D-G) . Consistent with previous 129 reports in macaques, various forms of microthrombi were still detectable on day 10 post-130 infection (Fig 1H) populations along with B cells, platelets, and a mixture of proliferating cells (Fig 2A) . Due 142 to PBMC isolation and cryopreservation, granulocyte populations were not accounted for 143 in this study. Myeloid and T/NK cell populations were selected for subsequent clustering. 144

We identified nine distinct T/NK cell subsets in PBMCs across all timepoints (Fig S2) . 145

Overall, we did not detect major alterations in the T/NK cell composition from PBMCs, but 146 at day 4 after infection, we did observe a drop in naïve CD8 T cells and an increase in 147 central memory CD4 + T cells (PBMC T/NK subpopulation 0 and 1, respectively) ( Fig S2) . abundance during infection. The major alterations in the CD14 + monocytes substantially 166 declined by day 7 post-infection and returned to baseline levels by day 10 (Fig 2C-D) . 167

The PGTS2-expressing monocytes that were lost at day 4 returned by day 10 post-168 infection, and did not show dramatic changes in gene expression (Fig 2C-D,G) . 169

In the BAL multiple distinct T cell and myeloid populations were identified, along 170 with proliferating cells, B cells, plasmacytoid DCs (pDC), MAST cells, and epithelial cells 171 ( Fig 3A) . Further clustering of BAL T cells identified 5 populations of T cells (Fig S2D) . 172

The largest change was the appearance on day 4 of a population with a mixture of CD8 

We measured multiple B cell subsets in PBMCs and BAL by flow cytometry, 208 including resting naïve B cells (CD20 + IgD + CD95 -), activated naïve B cells 209 (CD20 + IgD + CD95 + ), germinal center B cells (GC B cells: CD20 + IgD -BCL6 + Ki67 + ), 210

plasmablasts (CD20 + IgD-BCL-6 -CD38 hi CD27 + ), and activated memory B cells 211 (CD20 + IgD -BCL-6 -CD95 + ) (Figs S3A-B). Activated memory B cells were further 212 subdivided into IgM + , IgG + , IgA + , and isotype undefined. After infection, we observed a 213 decrease in total B cells in PBMCs (Fig S3C) , an increase of 2-3% in the proportion of 214 activated naïve B cells from PBMC at day 4 and 7 (Fig S3D) , and a decrease in the overall 215

proportion of activated B cells in PBMCs that are isotype undefined (Fig S3E) . At In addition to producing IFNg and TNF after peptide stimulation, the majority of Ag-243 specific CD8 T cells in the BAL also expressed granzyme B and degranulated after 244 restimulation, as indicated by CD107a/b surface staining ( Fig 4F) . Approximately 25-60% 245 of Ag-specific CD4 T cells in the BAL also made IL-2. Furthermore, both CD8 and CD4 246

Ag-specific T cells in the BAL upregulated markers of tissue residence, CD69 and CD103, 247 between days 7 and 10 post infection (Fig S4C-D) . Thus, SARS-CoV-2-specific CD8 and 248

Th1 cells, respectively. 250 251

tissues 253

At the day 10 necropsy, we examined SLO and NLT from the upper and lower 254 respiratory tract for bulk and Ag-specific T cells. Tissue resident memory CD8 and CD4 255 T cells (CD95 + CD69 + CD103 +/-) were detected in all nonlymphoid tissues measured, 256

including the lung, nasal turbinates, salivary glands, and tonsils ( Fig 5A-B ). CD103 + Trm 257 were more abundant among CD8 compared to CD4 T cells in the BAL, salivary glands, 258 and lymph nodes, which has been shown in other model systems 71,72 . Using intravenous 259 (i.v.) antibody staining to distinguish between tissue parenchymal and intravascular 260 cells 73-75 , we confirmed that most cells in the BAL, nasal turbinates, salivary gland, tonsils, 261 and lymph nodes were from the tissue parenchyma ( Fig S5) . As expected for such a 262 highly vascularized tissue, most cells from the lung tissue were intravascular stain 263 positive, but a small population of CD69 + ivcells were detectable in the lungs confirming 264 that tissue resident cells were also detected in pulmonary tissue. We next quantified the 265 magnitude of SARS-CoV-2-specific T cells in each of these tissues. S, N, and megapool-266 specific CD8 and CD4 T cells were detected in the BAL, previously PET hot lung lesions, 267 pulmonary lymph nodes, peripheral lymph nodes, spleen, and PBMC (i.e. the frequency 268 of IFNγ + and/or TNF + cells after peptide restimulation was statistically significantly higher 269 than the unstimulated samples). Surprisingly, Ag-specific CD8 and CD4 T cell responses 270 could not be detected in the majority of nasal turbinates, salivary gland, and tonsils (Fig  271   5C ). The absence of Ag-specific T cells cannot be accounted for by poor T cell isolation 272 from tissues ( Figure 5A -B) or lack of virus replication at these sites (Fig 1D-F) . Thus, the 273 early clonal burst of SARS-CoV-2-specific T cells is highly skewed toward the BAL and 274 unexpectedly undetectable in the nasal and oral mucosa. 275

Overall, the kinetics of SARS-CoV-2 replication and innate/adaptive immune 276 response in rhesus macaques appears typical of an acute viral infection ( Fig 5D) . SARS-277

CoV-2 replication peaks within 1 to 2 days post-infection and rapidly decreases thereafter. However, several scRNAseq studies from patients with COVID-19 have found that 299 inflammatory monocytes/macrophage populations are increased with disease 300 severity 2,11,12,14 , suggesting that early type I IFN responses are host protective but 301 prolonged activation of this pathway may be detrimental. 302

Ag-specific T cell responses were substantially greater in the BAL versus PBMCs, 303

with the average sum of spike, nucleocapsid, and membrane-specific T cells reaching 304 ~12% of CD4 T cells and ~7% of CD8 T cells in the BAL compared to ~1% and ~0. Alternative techniques for functionally agnostic detection of SARS-CoV-2-specific T cell 317 responses, such as the activation induced marker (AIM) assay, should be tested in future 318 studies 17,70,76 . There may also be T cells in these tissues specific to antigens other than 319 the ones tested here, although this too seems unlikely, as the peptide pools used contain 320 numerous immunogenic peptides from across the entire viral genome 69 . Lastly, it is 321 possible that T cells accumulate in these tissues after day 10, and further studies will be 322 needed to determine the longevity and breadth of SARS-CoV-2 specific T cell responses 323 in tissues at later time points. 324

Our findings support the hypothesis that control of primary SARS-CoV-2 infection in 325 these tissues is T cell independent, which is consistent with a report by Hasenkrug et al. 326 showing that rhesus macaques depleted of CD4 and/or CD8 T cells prior to SARS-CoV- (Table 1) . For infection, animals were anesthetized as described below and 362 administered 2x10 6 TCID50 total: 1x10 6 TCID50 in 3mL intratracheally with a plastic gavage tube 363 attached to 5 mL syringe, and 5x10 5 TCID50 in 0.5mL intranasally in each nostril. The animals 364 were examined daily with a health scoring sheet, as previously described 44 . Animals were 365 anesthetized with ketamine and dexmedetomidine at baseline (day -5 to -30), day 0, 1, 2, 3, 4, 7, 366 and 10 (necropsy) for exams, viral load swabs, blood and BAL fluid draws, and complete blood 367 count and C-reactive protein analysis. During anesthesia, animals were weighed and monitored 368 for heart rate, respiratory rate, body temperature, oxygen saturation. Glycopyrrolate and 369 atipamezole were given for recovery from anesthesia. 

Eluted RNA was stored at -80°C long-term.

Extracted RNA was used in a RT-qPCR reaction for detection of total or subgenomic RNA Biolegend's protocol respectively. Libraries were pooled and sequenced on an Illumina NovaSeq 538 S1 and S2 flow cells as per 10X sequencing recommendations.

The sequenced data was processed using cellranger (version 5.0) to demultiplex the 540 libraries. The reads were aligned to Macaca mulatta mmul_10 genome to generate count tables.

The count tables were then further processed and analyzed using the Seurat ( copies/mL by RT-qPCR. Cutoff for positivity for genomic RNA is 3000 copies/mL, cutoff 619 for subgenomic RNA is 2500 copies/mL (nasal/throat) or 3000 copies/mL (BAL/plasma). 620 ID#DG4i. Graphs indicate the percent Ki67 + of Ag-specific CD8 and CD4 T cells 697 responding to megapool, S, and N peptides from BAL at day 7 and day 10 post infection. 698

Only samples with >35 data points were included. Paired t-test of day 7 vs. day 10 for 699 CD8 and CD4 separately, and CD8 day 10 vs. CD4 day 10. Ki67 staining was not done 700 for ID#DGCX and DG3V. (F) Representative flow cytometry plots of Granzyme B, 701

CD107a/b, and IL-2 expression by Ag-specific CD8 and CD4 T cells from the BAL after 702 S peptide stimulation at day 7 and day 10 post infection from ID#DG4i. Graphs indicate 703 the percent Granzyme B + , CD107a/b + , or IL-2 + of Ag-specific CD8 and CD4 T cells 704 responding to megapool, S, and N peptides from BAL at day 7 and day 10 post infection. 705

Only samples with >35 data points were included. Paired t-test of day 7 vs. day 10 for 706 CD8 and CD4 separately. Quantification of parenchymal CD4 + CD95 + and CD8 + CD95 + T cells (equivalent to i.v. 811 stain negative) from tissues at necropsy. DHGF and DHKM did not have i.v. stain. 812

lymph node, normal pulmonary lymph node, peripheral lymph node (axillary)

blood from ID#DHGF in unstimulated samples at day 10 post infection

Peripheral lymph node includes axillary, inguinal, and cervical 718 lymph nodes. Previously hot lung sections not done for DGCX and DG3V. Sidak's multiple 719 comparison test for values on CD8 vs. CD4 T cells for each tissue. (C) Tissue distribution 720 diagram and quantification of the frequency of Ag-specific

Animals are indicated by shapes and stimulation 724 peptide by color. Statistics are paired t-tests of stimulated vs. unstimulated for each 725 condition. Raw values not plotted. Ag-specific T cells from BAL and blood at day 10, was 726 shown in figure 4, with addition of CD8 megapool here

com (D) Representative summary graphs of the immune response to SARS-728

CoV-2 infection in rhesus macaques. Top graph: median genomic and subgenomic viral 729

Middle graph: mean frequency 730 of myeloid subpopulation 1 and 6 in BAL, as in figure 3. Bottom graph: mean frequency 731 of the sum of Ag-specific T cells (S+N+M peptide pools) in BAL

Viral RNA levels are not correlated with 735 disease severity. Correlation analysis of viral RNA and lung lesion severity

Correlation of genomic RNA and subgenomic RNA in copies/mL in nasal swabs (left 737 graph) and throat swabs (right graph) from day 1 to day 4, as shown in figure 1D

Correlation of genomic RNA and subgenomic RNA in copies/mL in BAL from day 4 and 739 day 7, as shown in figure 1D. (C) Correlation of genomic RNA and subgenomic RNA

copies/gram of tissue from day 10 in tissues with values >limit of detection, as shown in 741 figure 1E. (D) Correlation of genomic RNA (left graph) or subgenomic RNA

at day 1 in nasal swabs and the sum of lung lesion metabolic activity at day 3

Correlation of genomic RNA (left graph) or subgenomic RNA (right graph) at day 1 in the 744 nasal swabs and the sum of lung lesion size at day 3. (F) Correlation of genomic RNA 745 (left graph) or subgenomic RNA (right graph) at day 4 in the BAL and the sum of lung 746 lesion metabolic activity at day 3. (G) Correlation of genomic RNA

subgenomic RNA (right graph) at day 4 in the BAL and the sum of lung lesion size at day 748

Minor alterations in T cells and 751 NK cells in PBMC and BAL as measured by scRNAseq. (A,D) UMAP plot shows the 752 sub-clustering of PBMC T and NK cells (A) from Figure

Clusters were annotated with cell-types based on gene 754 expression patterns as shown on the dot plot and are identified with different numbers 755 and colors on the plots. (lower panels). (B,E) UMAP plots depict the kinetic of lymphoid 756 cells over time. (C,F) Fraction of cells present in each of the lymphoid cell clusters

Supplemental Figure 3. B cell responses after SARS-CoV-2 infection in rhesus 760 macaques. Quantification of different B cell subsets after SARS-CoV-2 infection

Representative flow cytometry gating strategy of B cells and B cell subsets (i.e., resting 762 naïve, activated naïve, germinal center B cells (GC B cells), plasmablasts, activated 763 memory and different isotypes IgG + , IgM + , and IgA + ) from the blood (A) and BAL (B) from

C) Quantification of total B cells from the blood and BAL over time

Quantification of different B 766 cell subsets in the blood and BAL as a frequency of total B cells. Showing the mean value 767 from all animals with standard error. Dunnett's multiple comparison test comparing values 768 to day 0. No BAL data on B cells was collected for DGCX and DG3V

Dunnett's multiple comparison test comparing values to day 0. DGCX and DG3V did not 771 have baseline values

previously hot 773 pulmonary lymph nodes, normal pulmonary lymph nodes, and lung sections at day 10 774 post infection. No data from the lungs of DGCX, DG3V, DGRX, and DG4i; previously hot 775 pulmonary lymph nodes from DGCX and DG3V; normal pulmonary lymph nodes from 776 DGRX; or peripheral lymph nodes from DGRX

Turkey's multiple comparison test. In G, significant difference in lung activated memory 778 subset vs. spleen, peripheral LN, previously hot and normal pulmonary LN. Significant 779 difference in activated naïve in lung vs. previously hot pulmonary LN. Significant 780 difference in resting naïve in lung vs. spleen, peripheral LN

H, significant difference in IgG + and unknown isotype in peripheral LN vs. spleen

IgA isotype 783 not quantified at day 10 necropsy. (I-K) Anti-spike IgG and IgM antibody responses in the 784 plasma and BAL at day 0 and day 10 post infection. (I) Anti-Spike IgG antibody titration 785 curves at day 0 and day 10 post-infection compared to uninfected and convalescent NHP 786 plasma

Significance 788 calculated with Sidak's multiple comparison test

Activation of bulk and antigen-791 specific T cell responses in the blood and BAL. (A) Bulk CD3 + , CD4 + CD95 +

CD8 + CD95 + responses overtime as a frequency of live cells in the blood and BAL

Significance indicated with Dunnett's multiple comparison test comparing individual 794 timepoint to baseline. Bottom set of graphs overlay the mean CD4 + CD95 + and 795

CD8 + CD95 + response with standard deviation. (B) Frequency of Ki67 + on bulk CD3 +

CD4 + CD95 + , or CD8 + CD95 + in the blood and BAL. Bottom set of graphs overlay the mean 797

Ki67 + on CD4 + CD95 + and CD8 + CD95 + response with standard deviation. Ki67 stain not 798 done in DGCX or DG3V. (C) Representative flow cytometry plots from ID#DG4i and 799 quantification of the frequency of CD69 + on Ag-specific CD4 and CD8 T cells from the

Paired t-test comparing day 7 vs. day 10 for CD4 801 and CD8 separately, and CD4 day 10 vs

Longitudinal immune profiling reveals key myeloid signatures 814 associated with COVID-19

Single-cell multi-omics analysis of the immune response in COVID-816

Clinical and immunological features of severe and moderate coronavirus 818 disease 2019

IL-6 and IL-10 as predictors of 820 disease severity in COVID-19 patients: results from meta-analysis and regression

Inborn errors of type I IFN immunity in patients with life-threatening 823 COVID-19

Autoantibodies against type I IFNs in patients with life-threatening 825 COVID-19

Impaired type I interferon activity and inflammatory responses in severe 827 COVID-19 patients

Inflammasomes are activated in response to SARS-CoV-2 829 infection and are associated with COVID-19 severity in patients

Dexamethasone modulates immature neutrophils and interferon 832 programming in severe COVID-19

Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive 834 protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-835 analysis

Severe COVID-19 Is Marked by a Dysregulated Myeloid 837 Cell Compartment

Single-cell landscape of bronchoalveolar immune cells in patients with 839 COVID-19

Complex Immune Dysregulation in COVID-19

Patients with Severe Respiratory Failure

Longitudinal profiling of respiratory and systemic immune responses 844 reveals myeloid cell-driven lung inflammation in severe COVID-19

Deep immune profiling of COVID-19 patients reveals distinct 847 immunotypes with therapeutic implications

Longitudinal analyses reveal immunological misfiring in severe COVID-850 19

Antigen-Specific Adaptive Immunity to SARS-CoV-2 852 in Acute COVID-19 and Associations with Age and Disease Severity

Distinctive features of SARS-CoV-2-specific T cells predict recovery 855 from severe COVID-19

CD8(+) T cells specific for conserved coronavirus epitopes 857 correlate with milder disease in COVID-19 patients

An immunodominant NP105-113-B*07:02 cytotoxic T cell response 860 controls viral replication and is associated with less severe COVID-19 disease

Neutralizing antibody levels are highly predictive of immune 863 protection from symptomatic SARS-CoV-2 infection

Evidence for antibody as a protective correlate for COVID-19 866 vaccines

Correlates of protection against symptomatic and asymptomatic SARS-868

CoV-2 infection

SARS-CoV-2 infection rates of antibody-positive compared with 870 antibody-negative health-care workers in England: a large, multicentre, prospective 871 cohort study (SIREN)

SARS-CoV-2 infection generates tissue-localized immunological 874 memory in humans

Peripheral and lung resident memory T cell responses against 876 SARS-CoV-2

Neuropathology of patients with COVID-19 in Germany: a post-878 mortem case series

What can we learn from brain autopsies in COVID-19? 881

Unspecific post-mortem findings despite multiorgan viral spread in 883 COVID-19 patients

A cohort autopsy study defines COVID-19 systemic pathogenesis

SARS-CoV-2 infection and persistence throughout the human body and 887 brain

COVID-19 treatments and pathogenesis including anosmia in K18-889 hACE2 mice

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

SARS-CoV-2 infection of human ACE2-transgenic mice causes 893 severe lung inflammation and impaired function

Generation of a Broadly Useful Model for COVID-19 Pathogenesis

Mouse model of SARS-CoV-2 reveals inflammatory role of type I 899 interferon signaling

Syrian hamsters as a small animal model for SARS-CoV-2 infection and 901 countermeasure development

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. 904

Simulation of the Clinical and Pathological Manifestations of 906

Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications 907 for Disease Pathogenesis and Transmissibility

Dose-dependent response to infection with SARS-CoV-2 in the ferret 910 model and evidence of protective immunity

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

Comparative 915 ACE2 variation and primate COVID-19 risk

Broad host range of SARS-CoV-2 predicted by comparative and 918 structural analysis of ACE2 in vertebrates

Respiratory disease in rhesus macaques inoculated with SARS-CoV-921 2

Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus 923

Age-related rhesus macaque models of COVID-19

Responses to acute infection with SARS-CoV-2 in the lungs of rhesus 927 macaques, baboons and marmosets

Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African 930

Green Monkeys but Not Rhesus Macaques

Comparative pathogenesis of COVID-19, MERS, and SARS in a 933 nonhuman primate model

Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics 935 in lungs of African green monkeys

SARS-CoV-2 infection of African green monkeys results in mild 938 respiratory disease discernible by PET/CT imaging and shedding of infectious virus from 939 both respiratory and gastrointestinal tracts

Intranasal exposure of African green monkeys to SARS-CoV-2 results 942 in acute phase pneumonia with shedding and lung injury still present in the early 943 convalescence phase

Cellular events of acute, resolving or progressive COVID-19 in 945 SARS-CoV-2 infected non-human primates

Medical imaging of pulmonary disease in SARS-CoV-2-exposed 948 nonhuman primates

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in 951 Nonhuman Primates

Immune correlates of protection by mRNA-1273 vaccine against 954 SARS-CoV-2 in nonhuman primates

mRNA-1273 protects against SARS-CoV-2 beta infection in 957 nonhuman primates

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus 962 macaques

Correlates of protection against SARS-CoV-2 in rhesus macaques. 964

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia 966 in rhesus macaques

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus 968 macaques

SARS-CoV-2 infection protects against rechallenge in rhesus 970 macaques

Prior infection with SARS-CoV-2 WA1/2020 partially protects 972 rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants

Recovery from Acute SARS-CoV-2 Infection and Development of 975

Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques

Major alterations in the mononuclear phagocyte landscape associated 978 with COVID-19 severity

The differential immune responses to COVID-19 in peripheral and lung 981 revealed by single-cell RNA sequencing

Human dendritic cell subsets: an update

A Sequence Homology and Bioinformatic Approach Can Predict 986

Candidate Targets for Immune Responses to SARS-CoV-2

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans 989 with COVID-19 Disease and Unexposed Individuals

CD4(+) resident memory T cells dominate immunosurveillance and 992 orchestrate local recall responses

Human Tissue-Resident Memory T Cells Are Defined by Core 995 Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites

Cutting edge: intravascular staining redefines lung CD8 T cell 998 responses

Defective positioning in granulomas but not lung-homing limits 1000 CD4 T-cell interactions with Mycobacterium tuberculosis-infected macrophages in 1001 rhesus macaques

Measurement of leukocyte trafficking kinetics in macaques by serial 1003 intravascular staining

Immunological memory to SARS-CoV-2 assessed for up to 8 months 1005 after infection

Subacute SARS-CoV-2 replication can be controlled in the absence of 1007 CD8+ T cells in cynomolgus macaques

Adaptive immune determinants of viral clearance and protection in 1010 mouse models of SARS-CoV-2

Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-1013 2-Infected Syrian Hamsters

Immune memory from SARS-CoV-2 infection in hamsters provides 1015 variant-independent protection but still allows virus transmission

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T 1018 cell immunity

T cell-oriented strategies for 1020 controlling the COVID-19 pandemic

Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell 1023 reactivity in infected or vaccinated individuals

PD-1 blockade exacerbates Mycobacterium tuberculosis infection 1026 in rhesus macaques

Plasticity of the Mycobacterium tuberculosis respiratory chain and its 1028 impact on tuberculosis drug development

Functional inactivation of pulmonary MAIT cells following 5-OP-RU 1031 treatment of non-human primates

Cell Hashing with barcoded antibodies enables multiplexing and 1034 doublet detection for single cell genomics